An intervention that delivered machine learning mortality predictions with behavioral nudges to oncology clinicians significantly increased the rate of serious illness conversations among all patients included in this study.
Cycle 3 of the FLASH study reported that patients taking SGX301 to treat cutaneous t-cell lymphoma saw improved responses and maintained a positive safety profile.
Researchers demonstrated for the first time that radiation remodels T-cell responses found within the tumors of patients with renal cell carcinoma.
Genmab recently announced positive topline results from part 2 of the Phase 3 CASSIOPEIA study examining daratumumab monotherapy as maintenance therapy to treat patients diagnosed with multiple myeloma.
Detection of ESR1 mutations in baseline ctDNA was associated with inferior progression-free survival and overall survival in patients with advanced HR-positive breast cancer treated with exemestane versus fulvestrant.
Results from NCI-MATCH support the feasibility and efficiency of using next-generation sequencing (NGS) to triage patients to investigational therapy, provided that a sufficiently large pool of agents is made available.